$TAK News

Takeda and Weave Bio collaborate on AI-driven automation in drug development

Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities

Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug

FDA OKs Takeda, Protagonist drug for rare blood cancer

How Expanded Nuvaxovid Royalties and Partner-led Execution Could Shape Novavax’s (NVAX) Investment Narrative

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open

KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Takeda’s ORZEYFUL Wins Japan Approval For Narcolepsy Type 1 After Phase 3 Studies Show Significant Improvements Across Evaluated Symptoms

Takeda (TSE:4502) Stock Looks Undervalued As AI Drug Discovery Progress Builds

Department Of Veterans Affairs Awards Takeda $5.6B Contract for Drugs And Biologicals Through 2031

Takeda nets first-in-class advantage on narcolepsy drug’s FDA go-ahead

Takeda approval ushers in new wave of sleep drugs

Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Takeda's ORZEYFUL Wins FDA Approval As First Orexin Therapy For Narcolepsy Type 1; U.S. Launch Planned Following DEA Scheduling

Takeda Pharmaceutical Company Limited (TAK) Q1 2026 Earnings Call Transcript

Takeda Pharmaceutical Q1 Earnings Call Highlights

CORRECTION: Takeda Pharmaceutical Co Affirms FY2026 Adj EPS Guidance of $3.01 vs $1.57 Est; Affirms FY2026 Sales Guidance of $29.585B vs $28.950B Est